



MacroGenics, Inc.
Investor Relations Department
9640 MEDICAL CENTER DRIVE
Rockville, MD 20850
United States

Visit IR website
Sign-up for Email alerts

NASDAQ: MGNX

Last Trade:	16.26
Trade Time:	4:00 PM ET Aug 22, 2017
Change:	0.74 (+4.768%)
Day Range	15.33 - 16.29
52-Week Range	14.36 - 32.68
Volume	88,666

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases. The company generates its pipeline of product candidates from its proprietary suite of next-generation antibody-based technology platforms. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceu... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Aug 9, 2017*
[MacroGenics to Present at the Wedbush PacGrow Healthcare Conference](#)
- Aug 2, 2017*
[MacroGenics Provides Update on Corporate Progress and Second Quarter 2017 Financial Results](#)
- Jul 26, 2017*
[MacroGenics Announces Date of Second Quarter 2017 Financial Results Conference Call](#)
- Jul 17, 2017*
[Phase 1 Data for Flotetuzumab, MacroGenics' CD123 x CD3 DART® Molecule, Accepted for Oral Presentation at ESMO Congress 2017](#)
- Jun 17, 2017*
[MacroGenics Presents Updated Data from Phase 1 Study of MGD010 at Annual European Congress of Rheumatology \(EULAR 2017\)](#)

Financials [\[View all \]](#)

- [Second Quarter Financial Results](#)
- Feb 28, 2017*
[Annual Report \(10-K\)](#)
- Apr 4, 2017*
[Proxy Statement \(DEF 14A\)](#)
- Aug 2, 2017*
[Quarterly Report \(10-Q\)](#)
- May 3, 2017*
[Quarterly Report \(10-Q\)](#)
- Nov 2, 2016*
[Quarterly Report \(10-Q\)](#)